APA (7th ed.) Citation

Kankam, M., Griffin, R., Price, J., Michaud, J., Liang, W., Llorens, M. B., . . . Vilardell, D. (2020). Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects. Advances in therapy, 37(5), 2373-2389. https://doi.org/10.1007/s12325-020-01327-9

Chicago Style (17th ed.) Citation

Kankam, Martin, Rhonda Griffin, Jeffrey Price, Josée Michaud, Wei Liang, Mariona Bassas Llorens, Ana Sanz, Bradley Vince, and David Vilardell. "Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects." Advances in Therapy 37, no. 5 (2020): 2373-2389. https://doi.org/10.1007/s12325-020-01327-9.

MLA (9th ed.) Citation

Kankam, Martin, et al. "Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects." Advances in Therapy, vol. 37, no. 5, 2020, pp. 2373-2389, https://doi.org/10.1007/s12325-020-01327-9.